The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
ASCO GI 2026
Presentations Supported by Bayer
January 8-10, 2026
Agenda of oral and poster presentations at the 2026 Gastrointestinal (GI) Cancers Symposium of the American Society of Clinical Oncology (ASCO).
Please see below to download a PDF for each presentation and view a video (where applicable). Access for each publication will be available after the congress presentation.
Please select a compound to navigate to all related publications.
TKI
Real-World Prospective Comparison of Sorafenib and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Study in Japan (KSCC HAMRET Study)
Date/Time:
Friday, January 9, 2026 | 11:30 AM – 1:00 PM PST
Session:
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Type:
Poster
Presenting Author:
Sadahisa Ogasawara
Abstract #:
562
Poster Bd #:
D5
Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01- HCRN GI23-643
Date/Time:
Saturday, January 10, 2026 | 7:00 AM – 7:55 AM PST
Session:
Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Type:
TiP Poster
Presenting Author:
Ibrahim Halil Sahin
Abstract #:
TPS260
Poster Bd #:
K20
